Abstract
BackgroundThe addition of bevacizumab or pembrolizumab to pemetrexed-platinum chemotherapy has produced significant clinical benefits to patients with untreated, advanced non-squamous non-small cell lung cancer (NSCLC) lacking targetable genetic aberrations. However, the direct comparison between these two first-line treatments needs to be investigated.MethodsWe retrospectively investigated the medical records of 102 patients with stage IIIB~IV non-squamous NSCLC, and without sensitizing EGFR/ALK/ROS1 alterations. All patients received pembrolizumab or bevacizumab plus pemetrexed-platinum chemotherapy as the first-line treatment between December 2018 to April 2021 at Fudan University Shanghai Cancer Center. Assessments included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs). We also evaluated the prognostic biomarkers in the overall population and explored potential predictive biomarkers to aid the selection of optimal treatment regimens.ResultsThe median PFS was 10.0 months in the pembrolizumab group and 9.2 months in bevacizumab group (HR = 1.006; P = 0.982), while the median OS was not reached in either group (HR= 1.193; P =0.714). ORR was 36.7% versus 43.4% (P = 0.548) and DCR was 89.8% versus 92.5% (P = 0.735) in the pembrolizumab and bevacizumab groups, respectively. In the overall study population, baseline lymphocyte to monocyte ratio (LMR) >1.95 (HR = 0.312, P < 0.001) was an indicator of longer PFS. The presence of baseline bone metastasis (HR = 4.107, P = 0.009), baseline lactate dehydrogenase (LDH) >300 U/L (HR = 4.300, P = 0.025) and LMR ≤1.95 (HR = 5.291, P = 0.039) were associated with inferior OS. Baseline neutrophil-to-lymphocyte ratio (NLR) ≤3.10 was predictive of significantly favorable OS in the bevacizumab combination treatment (HR = 5.073, P = 0.039). The safety profiles were generally comparable between the two groups.ConclusionsIn patients with chemotherapy-naive, advanced, non-squamous NSCLC who lack driver mutations, the efficacy and safety of pembrolizumab and bevacizumab when combined with pemetrexed-platinum were comparable. For patients with baseline NLR ≤3.10, the bevacizumab combination therapy elicited significantly better OS benefits.
Highlights
Despite the benefits of obtaining early diagnoses and interventions, approximately 57% of lung cancer patients are not diagnosed until the presence of metastatic disease
In the final analysis of the large, open-label, phase III IMpower150 study [19, 20], numerically but not statistically significant overall survival (OS) improvement was shown in atezolizumab -carboplatin-paclitaxel treatment compared with bevacizumab-carboplatin-paclitaxel treatment for metastatic non-squamous non-small cell lung cancer (NSCLC) patients, regardless of programmed death-ligand 1 (PD-L1) level, EGFR/ALK genetic alterations or baseline liver metastasis status
Consistent with the corresponding results in the IMpower150 study, the results of the current study found that the addition of pembrolizumab or bevacizumab to first-line standard chemotherapy generally conferred similar levels of clinical outcome improvements to patients
Summary
Despite the benefits of obtaining early diagnoses and interventions, approximately 57% of lung cancer patients are not diagnosed until the presence of metastatic disease. According to the KEYNOTE-189 trial, pembrolizumab plus pemetrexed and platinum has manifested significantly improved median progression-free survival (PFS, 9.0 vs 4.9 months; hazard ratio [HR] = 0.49) and median OS (22.0 vs 10.6 months; HR = 0.56) with manageable toxicity in untreated, metastatic non-squamous NSCLC patients without targetable mutations [9]. Despite their benefits to patients, it is still elusive about the selection criteria between bevacizumab and pembrolizumab. The direct comparison between these two first-line treatments needs to be investigated
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.